NASDAQ:ATXI - Avenue Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.21 +0.06 (+1.45 %)
(As of 07/18/2018 04:00 PM ET)
Previous Close$4.20
Today's Range$4.15 - $4.30
52-Week Range$3.28 - $7.40
Volume19,400 shs
Average Volume34,023 shs
Market Capitalization$42.74 million
P/E Ratio-2.42
Dividend YieldN/A
BetaN/A
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York.

Receive ATXI News and Ratings via Email

Sign-up to receive the latest news and ratings for ATXI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ATXI
CUSIPN/A
Phone781-652-4500

Debt

Debt-to-Equity RatioN/A
Current Ratio2.58
Quick Ratio2.58

Price-To-Earnings

Trailing P/E Ratio-2.42
Forward P/E Ratio-1.65
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.89 per share
Price / Book2.23

Profitability

EPS (Most Recent Fiscal Year)($1.77)
Net Income$-12,250,000.00
Net MarginsN/A
Return on Equity-107.04%
Return on Assets-87.17%

Miscellaneous

Employees2
Outstanding Shares10,550,000
Market Cap$42.74

The Truth About Cryptocurrencies

Avenue Therapeutics (NASDAQ:ATXI) Frequently Asked Questions

What is Avenue Therapeutics' stock symbol?

Avenue Therapeutics trades on the NASDAQ under the ticker symbol "ATXI."

How were Avenue Therapeutics' earnings last quarter?

Avenue Therapeutics Inc (NASDAQ:ATXI) announced its earnings results on Thursday, May, 3rd. The company reported ($1.03) EPS for the quarter, missing analysts' consensus estimates of ($0.69) by $0.34. View Avenue Therapeutics' Earnings History.

What price target have analysts set for ATXI?

2 brokers have issued 1 year price targets for Avenue Therapeutics' stock. Their predictions range from $8.00 to $11.00. On average, they expect Avenue Therapeutics' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 125.7% from the stock's current price. View Analyst Ratings for Avenue Therapeutics.

What is the consensus analysts' recommendation for Avenue Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avenue Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Avenue Therapeutics' key competitors?

Who are Avenue Therapeutics' key executives?

Avenue Therapeutics' management team includes the folowing people:
  • Dr. Lindsay Allan Rosenwald, Exec. Chairman (Age 63)
  • Dr. Lucy Lu, Pres, CEO & Director (Age 43)
  • Mr. Joseph Walter Vazzano, VP of Fin. & Accounting, Principal Financial Officer and controller (Age 34)
  • Dr. Scott A. Reines, Interim Chief Medical Officer (Age 71)

When did Avenue Therapeutics IPO?

(ATXI) raised $30 million in an initial public offering (IPO) on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer served as the underwriter for the IPO and National Securities Corp. was co-manager.

Has Avenue Therapeutics been receiving favorable news coverage?

Media coverage about ATXI stock has trended somewhat positive this week, according to Accern. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Avenue Therapeutics earned a media sentiment score of 0.22 on Accern's scale. They also gave press coverage about the company an impact score of 43.97 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Avenue Therapeutics?

Shares of ATXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Avenue Therapeutics' stock price today?

One share of ATXI stock can currently be purchased for approximately $4.21.

How big of a company is Avenue Therapeutics?

Avenue Therapeutics has a market capitalization of $42.74 million. The company earns $-12,250,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Avenue Therapeutics employs 2 workers across the globe.

How can I contact Avenue Therapeutics?

Avenue Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]


MarketBeat Community Rating for Avenue Therapeutics (NASDAQ ATXI)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  74 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  161
MarketBeat's community ratings are surveys of what our community members think about Avenue Therapeutics and other stocks. Vote "Outperform" if you believe ATXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.